Showing 41-45 of 63 :
Validation Of A Machine Learning Approach To Estimate Systemic Lupus Erythematosus Disease Activity Index Score Categories And Application In A Real-World Dataset

BMJ Journals Published: May 20, 2021 Read the Full Manuscript >>  Objective Use of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in routine clinical practice is inconsistent, and availability of clinician-recorded SLEDAI scores in real-world datasets is limited. This study aimed to validate a machine learning model to estimate SLEDAI score categories using clinical notes[…]

OM1 Launches Multiple Sclerosis Registry With More Than 20,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, July 14, 2021 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its multiple sclerosis (MS) registry. MS is an auto-immune, inflammatory disease that attacks the central nervous system (CNS) and causes a variety of neurological symptoms, such as muscle weakness, spasticity, fatigue, numbness, vision[…]

American Academy Of Dermatology Collaborates With OM1 To Empower More Measured & Precise Care And Treatments For Dermatology

BOSTON, April 8, 2021 /PRNewswire/ — OM1, a real-world outcomes and technology company, today announced a strategic collaboration with the American Academy of Dermatology (AAD) connecting the Academy’s DataDerm™ clinical data registry to OM1’s real-world data and evidence platforms. The AAD estimates that 1 in 4 Americans (more than 85 million) see a physician for[…]

Black Women Less Likely To Undergo Digital Breast Tomosynthesis

M.D. Alert Published: March 5, 2021 Read the Full Commentary >> (Reuters Health) – Women have better screening outcomes with digital breast tomosynthesis, but a new study suggests that Black women have less access to this imaging modality. Researchers examined data on 385,503 women screened at one of 63 U.S. breast imaging facilities between 2015[…]

OM1 Artificial Intelligence (AI) Shared Decision Aid Demonstrates Significant Improvement In Decision Quality And Surgical Outcomes For Knee Osteoarthritis

BOSTON, Feb. 18, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), health outcomes and technology company, today announced the publication of clinical trial results in JAMA Network Open demonstrating its tool, OM1™ Joint Insights, positively impacts decision quality, shared decision making, patient experience, and functional outcomes in adults with knee osteoarthritis (OA). In the U.S., more than 30 million adults[…]

1 … 7 8 9 10 11 … 13